Last reviewed · How we verify
follitropin alpha
Follitropin alpha stimulates the production of follicle-stimulating hormone (FSH) to induce ovulation and support follicular growth.
Follitropin alpha stimulates the production of follicle-stimulating hormone (FSH) to induce ovulation and support follicular growth. Used for Induction of ovulation and support of follicular growth in women with anovulatory infertility, Assisted reproductive technologies (ART) such as in vitro fertilization (IVF).
At a glance
| Generic name | follitropin alpha |
|---|---|
| Also known as | Gonal f, Gonal F, Puregon, Urofollitropin |
| Sponsor | Azienda USL Modena |
| Drug class | Gonadotropin |
| Target | FSH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Follitropin alpha is a recombinant DNA-derived human follicle-stimulating hormone (FSH) analog. It works by mimicking the action of natural FSH, which is essential for the growth and maturation of ovarian follicles. By stimulating FSH receptors, follitropin alpha promotes follicular growth and ovulation, making it a crucial medication for treating infertility and other reproductive disorders.
Approved indications
- Induction of ovulation and support of follicular growth in women with anovulatory infertility
- Assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Multiple pregnancy
- Headache
- Nausea and vomiting
- Abdominal pain
Key clinical trials
- An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (PHASE1)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin
- Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation. (PHASE3)
- A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants (PHASE1)
- Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers (PHASE1)
- A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China (PHASE3)
- rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- follitropin alpha CI brief — competitive landscape report
- follitropin alpha updates RSS · CI watch RSS
- Azienda USL Modena portfolio CI